Specialty Pharma Journal

Fulcrum Acquires Global Rights to Losmapimod, a Potential Therapy for Facioscapulohumeral Muscular Dystrophy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Fulcrum Therapeutics, a biotechnology company focused o…
FSD Pharma to Acquire Prismic Pharmaceuticals for $17.5 Million

TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD Phar…
FDA Approves Merck’s Keytruda in Combination with Inlyta as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United Stat…
Lilly Announces Positive Top-Line Results from its Phase 3 Study Evaluating Taltz in Non-Radiographic Axial Spondyloarthritis

INDIANAPOLIS, April 22, 2019 /PRNewswire/ — Eli Lilly and Company(NYSE: LLY) an…
Lilly and Avidity Biosciences Enter License and Research Collaboration in Immunology and Other Indications

INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ — Eli …

The 2017 Hepatitis C Treatment Landscape

February 22, 2017 Blog

Last year, 2016, brought a whirlwind of changes and progress to the hepatitis C field, …
Read More »
Understanding the Hepatitis C Testing Process

February 15, 2017 Blog
Potential New Medication for Lymphoma

February 8, 2017 Blog

Phase 3 Study of Darzalex Shows Efficacy and Safety in Patients with Newly Diagnosed Multiple Myeloma

December 5, 2018 Oncology

BEERSE, Belgium–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the …

GlaxoSmithKline to Acquire Cancer Biotech Tesaro for $5.1 Billion

December 5, 2018 Business News

LONDON and WALTHAM, Mass., Dec. 03, 2018 (GLOBE NEWSWIRE) — GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) today announced …

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE Immunotherapies AMG 420 And AMG 330

December 5, 2018 Oncology, Precision Medicine

THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating …

Genentech’s Hemlibra Provided Sustained Bleed Control in the Largest Pivotal Study to Date of Children With Hemophilia A With Factor VIII Inhibitors

December 5, 2018 Hemophilia

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: …

Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla Oncotype DX Genomic Prostate Score Test

December 5, 2018 Business News, Oncology, Technology & Devices

REDWOOD CITY, Calif., United States, and MECHELEN, Belgium, 3 December 2018 – Genomic Health, Inc. the world’s …

Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of Fintepla in Dravet Syndrome

December 5, 2018 Rare Diseases

EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) — Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing …

FDA Grants Priority Review to Novartis’ AVXS-101, a One-Time Treatment Designed to Address the Genetic Root Cause of SMA Type 1

December 5, 2018 FDA News, Rare Diseases

Basel, December 3, 2018 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has …

FDA Grants Breakthrough Device Designation to Artificial Intelligence Software for CTEPH Pattern Recognition from Bayer and MSD

December 5, 2018 FDA News, Pulmonary Diseases, Technology & Devices

Berlin, December 3, 2018 – Bayer announced today that the U.S. Food and Drug Administration (FDA) …

HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Genentech

December 5, 2018 Business News, Technology & Devices

CHENGDU, China–(BUSINESS WIRE)–HitGen Ltd today announced that it has entered into a drug discovery research …

bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Study of Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Multiple Myeloma

December 5, 2018 Oncology

CAMBRIDGE, Mass. & SUMMIT, N.J.–(BUSINESS WIRE)–bluebird bio, Inc. (Nasdaq:BLUE) and Celgene Corporation (NASDAQ:CELG) announced initial …

Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab

December 5, 2018 Biosimilars, Oncology

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) announced today at the American Society of Hematology Annual Meeting …

Kite Announces Two-Year Data for Yescarta in Patients With Refractory Large B-Cell Lymphoma

December 5, 2018 Oncology

SAN DIEGO–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal …

Seattle Genetics Highlights Additional Analyses from Phase 3 Trial of Adcetris in Newly Diagnosed Advanced Hodgkin Lymphoma

December 5, 2018 Oncology

SAN DIEGO, Calif.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical …

FDA Authorizes First Test to Aid in Detecting Cytomegalovirus in Newborns

December 5, 2018 FDA News, Technology & Devices

Today the U.S. Food and Drug Administration permitted marketing of a new diagnostic test to …

FDA Accepts Editas Medicine’s IND Application for its CRISPR Genome Editing Medicine Being Investigated for Leber Congenital Amaurosis type 10

November 30, 2018 FDA News, Precision Medicine, Rare Diseases

CAMBRIDGE, Mass., Nov. 30, 2018 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (NASDAQ: EDIT), a leading …

Page 30 of 226« First...10 20 28 293031 32 »40 50 60...Last »

Recent Posts